MedTrace Logo

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

NCT01914380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 988

Last updated 2018-03-29

No results posted yet for this study

Summary

The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Conditions

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Patients will be followed-up for 24 months

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-29
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01914380 on ClinicalTrials.gov